Found: 4
Select item for more details and to access through your institution.
SUNMO: PHASE III TRIAL OF MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN IN RELAPSED/REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMA.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 170, doi. 10.1002/hon.3163_T05
- By:
- Publication type:
- Article
MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 122, doi. 10.1002/hon.3163_83
- By:
- Publication type:
- Article
POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA.
- Published in:
- Hematological Oncology, 2017, v. 35, p. 90, doi. 10.1002/hon.2437_79
- By:
- Publication type:
- Article
A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB COMBINED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA (NHL).
- Published in:
- Hematological Oncology, 2017, v. 35, p. 137, doi. 10.1002/hon.2437_126
- By:
- Publication type:
- Article